Montelukast Ratiopharm (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Ratiopharm, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It is used to manage asthma, exercise‑induced bronchoconstriction, and allergic rhinitis in adults and children as prescribed by a healthcare professional.

GNH USA supplies Montelukast Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway and nasal inflammation. - Asthma: improves control of chronic asthma and reduces frequency of exacerbations. - Exercise‑induced bronchoconstriction: prevents narrowing of airways triggered by physical activity. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Upper respiratory tract infection: transient symptoms. - Abdominal pain: occasional discomfort. - Cough: non‑productive. - Diarrhea: mild episodes. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Mood changes: including depression or suicidal thoughts. - Allergic reactions: such as angioedema or anaphylaxis. - Hepatotoxicity: elevated liver enzymes. - Stevens‑Johnson syndrome: severe skin eruption. - Churg‑Strauss syndrome: vasculitis with eosinophilia. - Severe bronchospasm: paradoxical worsening of breathing.

Before initiating therapy, consider the following precautions: - Pregnancy: safety not established; discuss risks with a healthcare provider. - Breastfeeding: assess benefit‑risk balance before use. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant asthma therapy: do not replace inhaled corticosteroids or bronchodilators. - Monitoring: observe for neuropsychiatric symptoms, especially in children. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Montelukast may interact with several medicines; awareness of interaction severity is important.

Major Interactions (Avoid): - Phenobarbital: may reduce montelukast plasma concentrations. - Rifampin: strong enzyme inducer that can lower drug exposure.

Moderate Interactions (Monitor Closely): - Antidepressants (e.g., fluoxetine): potential for additive neuropsychiatric effects. - Antihistamines: may increase risk of drowsiness. - CYP2C9 inhibitors (e.g., fluconazole): could modestly raise montelukast levels. - Warfarin: monitor INR as theoretical interaction exists. - Oral contraceptives: no clinically significant effect, but monitor for any unexpected changes.